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Abstract
Fabry disease (FD) is an X-linked hereditary defect of glycosphingolipid storage caused by mutations in the gene encoding
the lysosomal hydrolase a-galactosidase A (GLA, a-gal A). To date, over 400 mutations causing amino acid substitutions
have been described. Most of these mutations are related to the classical Fabry phenotype. Generally in lysosomal storage
disorders a reliable genotype/phenotype correlation is difficult to achieve, especially in FD with its X-linked mode of
inheritance. In order to predict the metabolic consequence of a given mutation, we combined in vitro enzyme activity with
in vivo biomarker data. Furthermore, we used the pharmacological chaperone (PC) 1-deoxygalactonojirimycin (DGJ) as a
tool to analyse the influence of individual mutations on subcellular organelle-trafficking and stability. We analysed a
significant number of mutations and correlated the obtained properties to the clinical manifestation related to the mutation
in order to improve our knowledge of the identity of functional relevant amino acids. Additionally, we illustrate the
consequences of different mutations on plasma lyso-globotriaosylsphingosine (lyso-Gb3) accumulation in the patients’
plasma, a biomarker proven to reflect the impaired substrate clearance caused by specific mutations. The established
system enables us to provide information for the clinical relevance of PC therapy for a given mutant. Finally, in order to
generate reliable predictions of mutant GLA defects we compared the different data sets to reveal the most coherent
system to reflect the clinical situation.
Citation: Lukas J, Giese A-K, Markoff A, Grittner U, Kolodny E, et al. (2013) Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New
Classification System in Fabry Disease. PLoS Genet 9(8): e1003632. doi:10.1371/journal.pgen.1003632
Editor: Atul Mehta, University College London, United Kingdom
Received January 12, 2013; Accepted May 14, 2013; Published August 1, 2013
Copyright:  2013 Lukas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study has been supported partially by an unrestricted scientific grant from Shire Human Genetic Therapies (Germany). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: arndt.rolfs@med.uni-rostock.de
Introduction
With a suspected prevalence of 1:3,100 to 13,341 [1],[2], Fabry
disease (FD, OMIM #301500) is the second most frequent
lysosomal storage disorder. FD causes the accumulation of
intracellular/lysosomal, plasma and urinary globotriaosylceramide
(Gb3) which, due to mutations within the a-galactosidase A (GLA,
Xq22) gene, cannot be cleared. Defects of the GLA gene product,
caused mostly by single amino acid substitutions, lead to its early
degradation within the endoplasmic reticulum [3] and prohibit
intracellular trafficking of the enzyme to the destination organelle,
the lysosome. In affected patients, typical FD presents as a
multisystemic disorder and in classic cases stroke, acroparaesthe-
sia, hypohidrosis, angiokeratoma, cornea verticillata, cardiac and
kidney disease [4],[5] develop. However, milder mono- or
oligosymptomatic cases have been reported [6]–[9]. Oligosympto-
matic cases further impede the diagnosis, e.g., large numbers of
abnormal variant forms of GLA found in newborn-screenings are
either linked to a monosymptomatic and late onset of the disease
[1],[2] or are coincidental findings that can be considered as
variants without significant metabolic consequences. Some other
mutations seem to be related to a certain phenotype with a
predominantly single organ involvement, hence, both a cardiac
variant [10]–[12] and a cerebrovascular variant [13] have been
described. Typically these mutations are associated with a late
onset phenotype. There appears to be at least one mutation
(p.D313Y), most likely a polymorphism [14],[15] but which can
also be found in stroke of unexplained aetiology [13],[16].
Due to the X-linked mode of inheritance, genetic sequencing in
females is the only valid tool to diagnose FD, since enzyme activity
in patient leucocytes can be in the normal range in a high number
of female heterozygotes [17], even in those severely affected.
Because of the X-linked inheritance, two thirds of all Fabry
patients can be expected to be females.
Globotriaosylsphingosine (lyso-Gb3), a deacylated metabolite of
Gb3 has been described as a useful biomarker to quantify the
burden of FD. Lyso-Gb3 was shown to be the storage material in
many cells accumulating to high levels in vasoendothelial cells of
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blood vessels. Lyso-Gb3 was proven to be more specifically
increased in FD patients [18] than Gb3 and demonstrated to be
reduced in mice under enzyme replacement therapy (ERT).
Moreover, lyso-Gb3 has been proposed to take part in the
development of FD nephropathy [19] and general inflammatory
processes. Even though lyso-Gb3 can be used as a reliable
biomarker for FD, it is only reliable for monitoring as no absolute
correlation has been described between the nature of the mutation
and lyso-Gb3 levels. It was concluded that long periods of
exposure to this agent lead to the development of symptoms [20].
Several recent studies tried to generate more impartial data
about the cellular and structural consequence of a given GLA
mutation. They were typically based on overexpression systems
and analysed either the residual GLA enzyme activity [21] or
focussed on enzyme trafficking and stability aspects [3]. Other
studies tried to establish genotype/phenotype correlations in
clinical cases of Fabry patients [22]. The elucidation of the crystal
structure of the enzyme [23] was the basis for the establishment of
structure/function correlation models [24]–[26].
In a recent study, newly described mutations were analysed in
an overexpression system. Enzyme activity was measured and
responsiveness to 1-deoxygalactonojirimycin (DGJ) was tested in
Western blot assay and in patient’s T-lymphocytes [27]. This
approach was used to determine the likelihood of a newly
identified GLA variant leading to FD. Wider studies with T-
lymphocytes have previously been undertaken [28],[29]. A
systematic approach to examine a broad range of mutations has
been developed in order to facilitate diagnosis and therapeutic
decisions [30].
In the present study 171 GLA mutations were characterised
biochemically for residual enzyme activity, degradation status and
behaviour towards pharmacological chaperone (PC) DGJ. More-
over, the obtained data sets were compared with patient plasma
lyso-Gb3 levels, the computational prediction algorithm Poly-
Phen2 (Polymorphism Phenotype v2) [31] and the clinical
phenotype. We paid particular attention to mutations believed
to be on the borderline for causing the disease.
Results
Determination of single amino acid substitution
mediated a-galactosidase A damage
We tested 171 mutations with regard to enzyme activity and
degradation status to evaluate which mutation leads to diminished
enzyme activity. Among the mutations tested, 50 had not been
described previously., In sum, 158 missense, 6 nonsense mutations
causing immediate polypeptide abort, 4 small deletions (1–2
nucleotides) and 3 small insertions (1–4 nucleotides) were
examined for potential damage (Table S1). Mutant enzymes were
studied with respect to their effect on protein degradation and
pharmacological chaperone responsiveness (Figure S1).
Enzyme activity and intracellular enzyme level were correlated
for mutations natively displaying activities above 6% (Spearman
correlation coefficient rs = 0.866, p,0.001) (Figure 1B). Enzyme
levels were not associated with residual activity since highly
defective enzymes seemed to lack the capacity to process the
substrate (Spearman correlation coefficient rs = 0.128, p= 0.272)
(Figure 1A). Figure S1 shows enzyme content for some strongly
affected enzymes (e.g. p.D231N, p.L275F and p.L415P) with no
measurable activity. Overexpressed mutant a-Gal A was abun-
dantly present in the cells, notably above the endogenous level at
the expected size of 46 kDa. Thus, the protein was evidently
processed [32], but it is not catalytically active. A closer look at
position p.Arg118 (buried residue) revealed that the actual
described mutation for this moiety (p.R118C) displayed the lowest
detected enzyme activity at about 20% of the wild type enzyme
(Figure 2). All other mutations at this position (e.g. R118G,
R118S, see Table S1) were less severely affected (range 20–70.9%).
Vice versa, at position S126 (stabilising loop), the described
mutation S126G displayed the mildest effect on activity loss. The
strong decrease of activity for S126C is explained by the chemical
nature of the amino acid exchange from serine to cysteine,
predicted to disrupt protein conformation (due to auxiliary
disulphide bond introduction). As expected when changing the
important aspartate residue at position 264 (close active site) [33],
the enzyme lost its activity. The only exception was p.D264N
which maintained about 37.9% of its activity. We arranged 4
classes of mutations based upon the enzyme activity data: class I:
0%, class II: .0%–20%, class III: $20%–60%, class IV: $60%
for further analyses.
Responsiveness to pharmacological chaperone DGJ
In order to examine the importance of enzyme activity for
clinical and therapeutical decisions, we analysed enzyme activity
changes after addition of the pharmacological chaperone DGJ. In
order to simplify the outcome measures, a responder was defined
as a mutation whose activity was increased 1.5-fold or .5%
compared to the untreated value. Under this directive, 42.8% of
the missense mutants were responsive to DGJ. Mutations in sites
p.Arg118, p.Ser126 and p.Asp264 gave rise to enzymes that
displayed an overall minor (if any) increase of activity through
DGJ treatment indicating that the moieties are generally situated
in sites where treatment with the PC does not result in significant
elevation of a-Gal A activity and that the type of amino acid
substitution is biochemically less relevant (exception: p.D264N, see
also Table S1). Furthermore, DGJ analysis showed that active-site-
associated amino acid substitutions (p.D93E/Y, p.D170N, p.R227Q
and p.D231N) could not retain lost activity under treatment.
DGJ responsiveness was highly associated with residual activity
of the mutant enzyme in vitro (p,0.001 in linear trend test, Table
S2). Class I mutants were less likely to respond to PC treatment
(14.5%) than class II mutants (82.8%) with a less severe impact on
Author Summary
Fabry disease is caused by a single gene deficiency. It is the
second most common lysosomal storage disorder and the
result is a build-up of glycosphingolipids in different areas
of the body (kidneys, intestine, etc). It is an important
consideration for clinicians in the diagnosing of stroke,
kidney and cardiovascular diseases. Many symptoms of
Fabry are seen in other diseases as well (both inherited and
non- inherited), which makes diagnosis difficult. We
observed numerous novel mutations in patients that
displayed a monosymptomatic, however life-threatening
course of Fabry disease. This prompted us to study and
characterise those mutations with regard to their bio-
chemical and clinical consequences. Overall, 171 Fabry
mutations were considered in an overexpression system
for the prediction of the clinical course of Fabry disease.
Furthermore, we highlight the usefulness of the in vitro
system that we developed which will help with therapeu-
tical decisions, by testing the responsiveness of mutant
enzymes to the pharmacological chaperone DGJ. This
work aims to draw the attention of clinicians and
researchers to milder forms of Fabry disease which might
at first appear unrelated to this clinically heterogenous
disease.
Functional Characterisation of GLA Mutations
PLOS Genetics | www.plosgenetics.org 2 August 2013 | Volume 9 | Issue 8 | e1003632
Figure 1. Correlation analysis of a-Gal A level (semi-quantitative Western Blot) and activity. A: No correlation between GLA level and
residual activity for mutations possessing less than 6% residual activity (n = 76, Spearman correlation coefficient rs = 0.128, p = 0.272). This implies that
the catalytic unit is affected by the mutation and thus high amount of enzyme cannot compensate for the loss of activity. B: For mutation possessing
more than 6% residual GLA activity (n = 48), the in vitro enzyme activity and GLA levels correlate with each other, indicating that the catalytic core is
still intact and mutation most likely affect protein trafficking (Spearman correlation coefficient rs = 0.866, p,0.001).
doi:10.1371/journal.pgen.1003632.g001
Figure 2. In vitro activity of specific GLA site mutations. Note that mutations at position p.Asp264 almost always lead to a loss of GLA activity,
while the same does not hold true for p.Arg118 and p.Ser126. Interestingly mutations in p.R118 do not lead to a loss of activity below 20% of WT and
range from 20% to 80% while p.Ser126 can lose all activity with certain mutations and retains no more than 60% activity. This highlights the
differential effects of the mutational site and amino acid change on a-Gal A activity. Given is the median activity of all mutations in each position
(horizontal mark).
doi:10.1371/journal.pgen.1003632.g002
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enzyme function. Most of the best responders belong to this
category (p.A156V, p.I253S, p.R301Q, etc.). In classes III and IV, a
high percentage of responders was present (71.4 and 63.2%
respectively), though with a high number of only weakly stimulated
enzymes.
Association of different parameters
In a first approach, we compared residual enzyme activity to
biomarker levels obtained from patients with the according
mutations to investigate whether in vitro data reflect lyso-Gb3 as
a marker for clinical severity.
To make sure that lyso-Gb3 was an adequate FD measure for
testing of in vitro enzyme activity accuracy, we ascertained that
lyso-Gb3 in male and female Fabry patients (Figure 3) were
considerably higher than lyso-Gb3 in healthy controls [34]. The
pathological cut-off for lyso-Gb3 measurements was set to 0.9 ng/
ml (95th percentile of healthy individuals).
The gender-dependence of lyso-Gb3 values in hemizygote
males and heterozygote females carrying the same mutation
(compare Table S1) reflects the shortcoming of patient-derived
data. Still, the median values of the patient/proband cohorts
showed values above the pathological cut-off in both males and
females (5.5 ng/ml for female individuals, 28.6 ng/ml for males).
In figure 3 coloured dots represent patients with the mutations
p.S126G, p.A143T and p.D313Y, including most of the values not
detected as pathological. Strikingly, the overall inconspicuousness
of mutations such as p.A143T or p.D313Y (see mean values in
Table S1) was not gender-dependent, meaning that those patients
would remain undetected in males and females alike. However,
Table S3 shows that lyso-Gb3 displays sensitivity for classic
mutations. Depicted is another set of mutations found in patients
where we measured plasma lyso-Gb3. In this table, most of the
mutations led to a complete loss of the enzyme (truncations, splice
mutations, etc). The positive predictive value for lyso-Gb3 (for all
355 FD patients and 180 control individuals, Figure 3) was 95%.
The negative predictive value was 60.9%.
Female and male biomarker data were analysed separately to
evaluate the association between enzyme activity and levels of the
biomarker lyso-Gb3. For the categorisation of lyso-gb3-values we
used the following cut-points: class I: lyso-gb3 $80/10 ng/ml for
males/females, class II: lyso-gb3 20–80/5–10 ng/ml for males/
females, class III: lyso-gb3 0.9–20/0.9–5 ng/ml for males/
females, class IV: lyso-gb3,0.9 ng/ml (for males/females). The
enzyme classes were strongly associated with the biomarker levels
of the patients (p,0.001 for males and for females, linear trend
test, Table 1). Mutations with an activity lower than 20% showed
gender-independent elevated lyso-Gb3 values.
Trend test analysis revealed statistically significant associations
with enzyme activity (p,0.001, linear trend test, Table 1). The in
silico prediction tool PolyPhen2 revealed strong association with
the enzyme activity classes as well (p,0.001)
In addition, we also considered the correlation of in vitro enzyme
activity with accessible surface area of the mutated amino acid
residues as a possible determinant for the biological consequence
of a given mutation as proposed previously [33]. However, we
found only a weak linear trend (for details see Table S2).
Association of enzyme activity reduction to clinical
phenotype
Table 2 shows the proportion of mutations correctly classified
into the clinical phenotype groups by using lyso-Gb3 values of
females, males, in vitro enzyme activity and PolyPhen2 scores.
Enzyme activity showed the highest rates of correct classification
both for 72 mutations where data were available and for 21
mutations for which we had values in all four measures (PolyPhen2
scores, lyso-Gb3 for females, lyso-Gb 3 for males and enzyme
activity). The classification rates were 83% for 72 mutations and
86% for the subset of 21 mutations. Lyso-Gb3 for males and
PolyPhen2 scores showed similar prediction quality: PolyPhen2
scores led to a slightly higher classification rate of 76% in the
subset compared to 71% for lyso-Gb3 values for males. With 67%
in the subset of mutations lyso-Gb3 values for females showed the
lowest rate of correctly classified mutations.
Discussion
The validity of potential biomarker lyso-Gb3
Until now, biomarker data for novel mutations have been
regarded as the gold standard for diagnosis (5) immediately
following genetic diagnosis. This may not be accurate for milder
cases of the disease, for example when the patient is tested early in
the development of the disease (even though an age dependent
increase is still speculative) or the mutation leads to a minor catalytic
defect, since we failed to detect our p.S126G, p.A143T and p.D313Y
patients (mean values are non-pathological, see Table S1) as well as
three (female) p.N215S cases. This is in accordance with recent
findings [35]. We reported a family with only female mutation
carriers [36]. In the case of an unknown mutation this is a difficult
situation, because lyso-Gb3 analysis is less strongly associated with
disease phenotype in females (Table 2). For some newly described
mutations, we lacked a detailed clinical description, however the
Figure 3. Lyso-Gb3 values for female and male Fabry patients
compared to control. The horizontal mark indicated the median. It is
noteworthy that lyso-Gb3 levels in males are ,10 times higher than in
females. Each data point represents one patient. Indicated in pink are
patients with the mutation p.S126G (8f/4m), in blue p.A143T (10f/8m)
and in green p.D313Y (33f/24m) to illustrate that most found non-
pathogenic mutations belong to either one or the other patient cohort.
Other exceptions are: p.R118C, p.V316I, p.E418G (one male patient each)
and p.A20P, p.D83N, p.I91T, p.S102L, p.R112C, p.R118C, p.D175E, p.G325S,
p.A368T, p.T385A, p.W399*, c.1208delT, p.L415F, (one female patient
each) and p.R252T (46), p.N215S (36). About 180 healthy probands
were tested with no Fabry gene variation and had values of 0.9 ng/ml
(95th percentile calculation).
doi:10.1371/journal.pgen.1003632.g003
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phenotype and hence rationale for FD testing was either stroke (e.g.
p.D83N, p.S102L, p.N139S, p.R252T, p.V316I, p.L415F, p.E418G),
kidney disease (e.g. p.A37T, p.H225D, p.E398A) or in one case
cardiological symptoms (p.R220Q) of unexplained etiology. A
surprisingly high number of these missense mutations was found
in oligosymptomatic patients and in the event of low lyso-Gb3 and
high residual activity values. About 7.1% of males and 16.7% of
females lyso-Gb3 (mean) of all mutations examined (Table S1) were
within the non-pathogenic range. However, if we subtract all
mutations related to mono- or oligosymptomatic FD, lyso-Gb3 is
pathogenic for 100% of males and 96.9% of females. The remaining
3.1% of females harbour the following mutations: p.A20P, p.I91T,
p.W262* and p.W399*. The truncating mutation p.W262* has not
been described before but is expected to cause classic FD. The
biomarker lyso-Gb3 demonstrated a weaker association to clinical
phenotype than in vitro enzyme activity for each mutation studied.
Table S3 shows additional 52 mutations for which biomarker data
was collected. All classical mutations showed elevated values above
the normal range in males.
For each mutation studied mean lyso-Gb3 values were always
higher in male than in female patients (higher sensitivity in males).
However the values obtained in females also accurately reflect
disease pathology (similar specificity). It has to be emphasised that
every mutation causing a pathological lyso-Gb3 mean value in
males also demonstrates with a pathologically elevated mean value
in females. In the same vein, the mutation N215S that has a higher
Table 1. Association of in vitro enzyme activity and clinical and computational parameters.
enzyme activity
0% .0%–20% $20%–60% $60% p (for linear trend test)
disease phenotype
classic 42 8 2 0 ,0.001
classic/variant 3 1 3 0
variant 1 2 6 4
lyso-gb3 male
I ($80 ng/ml) 9 0 0 1 ,0.001
II (20–80 ng/ml) 16 3 0 0
III (0.9–20 ng/ml 4 2 3 1
IV(,0.9 ng/ml) 0 0 3 3
lyso-gb 3 female
I ($10 ng/ml) 5 0 0 0 ,0.001
II (5–10 ng/ml) 13 1 0 0
III (0.9–5 ng/ml) 9 4 4 1
IV (,0.9 ng/ml) 0 0 4 7
PolyPhen2
benign 5 2 12 13 ,0.001
possibly damaging 8 7 4 1
probably damaging 68 14 11 2
Statistical association of enzyme activity and other parameters indicative for Fabry disease. The matrix confirms the high degree of translatability of in vitro data to the
individual patients’ biomarker phenotype. Lyso-Gb3-based classes of the mutants are fitting the enzyme activity classes.
doi:10.1371/journal.pgen.1003632.t001
Table 2. In vitro enzyme activity reflects clinical phenotype and is a predictor for FD.
Lyso-Gb3 for females Lyso-Gb3 for males In vitro enzyme activity PolyPhen2 classes
N= 33 N=32 N=72 N= 72
Nagelkerkes R2 0.44 0.41 0.53 0.12
22 Log Likelihood (df) 12.44 (3) 14.43 (3) 15.41 (3) 16.13 (2)
Mutations correct classified 69.7% 78.1% 83.3% 73.6%
N= 21 N=21 N=21 N= 21
Nagelkerkes R2 0.45 0.40 0.82 0.53
22 Log Likelihood (df) 12.91 (3) 13.44 (3) 4.18 (3) 7.80 (2)
Mutations correct classified 66.7% 71.4% 85.7% 76.2%
Comparison of prediction quality for different parameters with regard to clinical phenotype (classic, variant, classic/variant, see Table S1); variance estimates from
ordinal regressions for the outcome ‘clinical phenotype’ with different covariates, 1. for all data available in the particular dimension, 2. for a subset of 21 mutations that
have values in all dimensions.
doi:10.1371/journal.pgen.1003632.t002
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frequency in the population manifests with a mean value of
4.2 ng/ml (male) obtained from 7 different patients displaying
increased lyso-Gb3 and 1.1 ng/ml (female) obtained from 6
different patients. However, 3 of the females showed normal values
of 0.79 ng/ml, 0.68 ng/ml, one individual had a value below the
limit of quantitation (,LLOQ), respectively. Essentially, lyso-Gb3
is a marker of classic rather than uncertain FD, (i.e. monosymp-
tomatic or mild cases) reflecting disease severity after all. However,
to overcome the limitation of individual patient constitution, we
propose a new classification system based on in vitro enzyme
activity.
In vitro enzyme activity as a tool for diagnostic
management
Previous studies have focused on mutant enzyme activity, but
this has never been proposed for use as a diagnostic tool. In the
present study we utilised a cell culture model to generate
enzymatic data for a large subset of GLA mutations. As stated
before, Fabry disease-causing mutations are not limited to active
site residues [37], but rather distributed across the entire protein.
We therefore chose mutations in domains across the entire protein
(see also criteria in the Materials and Methods section). Herein, we
report and characterise 171 mutations on the basis of in vitro
overexpression and enzyme activity. Among the tested mutations,
50 (29.2%) had not been described previously (note: the p.Arg118,
p.Ser126 and p.Asp264 substitutions had not been found in patients
yet, see Table S1). A strong association to biomarker plasma lyso-
Gb3, the PolyPhen2 in silico prediction and the DGJ responsive-
ness of the mutation identifies those parameters as potential
predictors of the clinical phenotype of the mutations. However, in
vitro enzyme activity measurement was the most accurate predictor
of disease phenotype assigning 85.7% of the mutants to the correct
disease group whereas biomarker lyso-Gb3 for females and males
and PolyPhen2 analysis only predicted 66.7, 71.4 and 76.2%,
respectively, (as indicated by the highest explained variance in
regression (R2), lowest 22Log-Likelihood, and highest rate of
correct classified mutations, Table 2). The ability of the mutations
to respond to PC treatment classified 76.2% of the mutation
correctly (data not shown).
The predictive quality of PolyPhen2 is hampered especially
when it comes to mutations that are in unknown molecular
interaction sites or mutations in domains with unclear structural
significance, such as the N-terminal signal peptide region (i.e.
p.A15E is incorrectly predicted to display a benign impact on
enzyme function). However, the precision could assumingly be
enhanced using a specifically constructed algorithm as has been
conducted for the prediction of DGJ responding mutants in FD
[26]. The pharmacological chaperone DGJ can rescue unstable,
degradation-prone mutants, therefore responsiveness to DGJ
could be correlated with the level of damage of the mutation as
proposed previously [26]. Since only 14.5% of class I mutants
could be rescued with the pharmacological chaperone DGJ and
the proportion of responding mutations is much higher within the
other classes, residual activity is associated with whether a
mutation can be rescued or not (p,0.001, Table 1). As mentioned
before, the drawback for the lyso-Gb3 is reasoned by clinical
variability of the individual patients, especially in females.
Unknown and mild GLA mutations - the challenge to
establish pathogenicity
Due to the fact that genotype/phenotype correlations only exist
for severe GLA mutations and are mostly linked to the classic
phenotype, clinical decision-making in diagnosis and therapy in
Fabry disease is challenging. Further, the genotype/phenotype
correlation depends on the patients’ gender. However, there is no
doubt that clinicians would apply an ERT to a female patient with
a classic FD mutation as well as to males in pre-clinical or milder
forms of the disease, since therapeutic success is closely connected
to the correct treatment schedule and a timely onset of the
treatment to improve the probability of a complete symptom
reversal. Before the year 2000, p.D313Y had been described as the
only enzyme variant with high residual activity and was therefore
classified as a SNP. In contrast p.A143T which also has significant
residual activity [28],[38], was classified as a disease-causing
mutation [39] and also appears more frequent than usual FD
mutations. The number of mutations resulting in a milder disease
phenotype increased in the course of systematic screening
programs identifying mutations in patient cohorts with symptoms
common for other diseases. This highlights the need to re-consider
the approach to Fabry diagnosis.
Mutations with residual activity undergo early
degradation
Due to the fact that FD mutations can affect both the stability
and catalytic function of the enzyme we correlated the level and
activity of GLA enzyme (Figure S1, Figure 1). The mutations
p.D93E and p.D231N had GLA levels of 8.0% and 46.0% of wild
type respectively, but no residual activity. Both mutants responded
to the stabilising effect of DGJ, increasing GLA levels to 24.7%
and 66.7% respectively, but no increase in activity was detected
(Figure S1). In contrast to this finding class III and IV mutations as
well as milder affecting class II mutations (activity .6%) displayed
a strong correlation between GLA level and activity (Spearman
correlation coefficient rs = 0.866, p,0.001). This emphasises the
assumption that class III–IV (and the majority of class II)
mutations mainly demonstrate an early degradation defect that
retains enzyme activity. To test if mutations can affect stability
alone, we performed a kinetic assay. Many of the GLA variants
(p.A143T, p.A156V, p.R301Q, p.L310F) had unchanged kinetic
properties (Table S4) indicating that the main reason for the
molecular defect is early degradation. At least 3-fold higher
activity above endogenous GLA was necessary to calculate kinetic
parameters. Some of the mutations failed this criterion (p.R49G,
p.S65I, p.D231N and p.L415P had activities around 200 nmol 4-
MU/mg protein/hr which corresponds to endogenous GLA) and
were therefore excluded from the analysis. However, the finding
that even large amounts of enzyme could not increase activity
above the endogenous level of the HEK293H cells indicates a
severe impairment of the kinetic properties. Furthermore, this
analysis revealed one mutation provoking only a mild decrease in
enzyme activity, strong DGJ responsiveness and a benign in silico
prediction that might nevertheless significantly change the kinetic
properties of the enzyme (p.H46P). This could explain the disease
pathology in patients with this mutation, since an increased KM
value could lead to diminished intra-lysosomal substrate turnover.
Evidence rises that classification of mutants as either active site
mutations or enzyme stability-abolishing mutations may not
explain all aspects of the underlying defect. This was further
explored by analysing a possible impact on the splicing behaviour
resulting from the respective mutation. Supplementary Tables S5
A and B report on a few variants where the effect on splicing at
exon-intron junctions as well as on cryptic splicing sites may
contribute to their pathogenicity (for method see Text S1 in the
supplementary material). However, the majority of missense
mutations exhibit no noticeable effect on splicing.
Altogether, we propose to conduct all available testing (i.e. lyso-
Gb3, in silico and in vitro overexpression analysis) to determine the
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characteristics of novel GLA mutations even though in severe cases
it might be sufficient to test just one of the discussed parameters,
but detailed testing might reveal unforeseen damage to the enzyme
and its function. We point out the usefulness of a readily available
in vitro assay in deciding whether an ERT or alternative treatment
strategies (DGJ is currently being tested in clinical trials) should be
started and whether a patient should be treated after pre-
symptomatic genetic diagnosis at all, showing increased FD risk
(harbouring a mutation with residual activity lower 20%) or if a
frequent follow-up on the patient is initially more reasonable.
However, only epidemiologic studies could determine to which
extent mutations with a substantially lowered, yet high, enzyme
activity (e.g. p.D83N, p.S126G, p.A143T, p.D313Y) contribute to the
symptoms of Fabry disease and what role the degree of variation
plays among individuals.
Materials and Methods
Patients and blood samples
Blood samples were obtained from patients undergoing
biochemical analysis or genetic testing for verification of Fabry
disease by the Albrecht-Kossel-Institute for Neuroregeneration
(AKos). All patients agreed for testing of their blood samples. The
project was in concordance with the regulations of the local
Ethical Committee of the University Rostock.
Cell culture
HEK293H cells were maintained in DMEM (Dulbecco’s
Modified Eagle Medium, Invitrogen, Karlsruhe, Germany) supple-
mented with 10% FBS (fetal bovine serum; PAA Laboratories,
Pasching, Austria) and 1% penicillin/streptomycin (Invitrogen,
Karlsruhe, Germany). All cells were incubated in a water-jacket
incubator (Binder, Tuttlingen, Germany) at 37uC under 5% CO2
atmosphere. DGJ (Sigma Aldrich, Munich, Germany) was added to
the culture medium from an aqueous stock solution (10 mM).
Cloning of a-galactosidase A in an overexpression vector
A plasmid containing the full length cDNA of a-galactosidase A
(IRAUp969H0320D, aligned to accession no. NM_000169.2) was
obtained from ImaGenes GmbH, Berlin, Germany. Amplification
for subcloning was performed using cloned Pfu DNA polymerase
(Stratagene, La Jolla CA, USA), with the primers 59-AGGTCG-
GATCCG ACAATGCAGCTGAGGAACC-39 (forward) and 59-
GGTGTTCGAATTAAAGTAAGT CTTTTAATGACATCT-
GCA-39 (reverse) introducing unique restriction sites for BamHI
and BstBI. The amplicon was inserted into mammalian expression
vector pcDNA3.1/V5-His6 (Invitrogen, Karlsruhe, Germany).
Site-directed mutagenesis of a-galactosidase A
Expression vectors harbouring a-Gal A mutations were
generated by site-directed PCR mutagenesis (3,28) using the
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA). Nucleotide exchanges, deletions or insertions
were individually introduced by PCR amplification with PfuUltra
DNA polymerase, the pcDNA3.1/GLA plasmid vector containing
the wild type sequence was used as template and a 27–37-mer
primer set, with sense and antisense primers carrying one of the
respective sequence modifications central to their length. Each
mutant plasmid was sequenced on a 3130 xl Genetic Analyzer
(Applied Biosystems, Darmstadt, Germany).
Transient expression of mutant enzymes in HEK293H cells
1.56105 cells were seeded 24 hours before transfection in each
well of a 24-well culture plate using 500 ml DMEM medium
(Invitrogen, Karlsruhe, Germany) supplemented with 10% Fetal
bovine serum (PAA Laboratories, Pasching, Austria). Transient
expression of mutant enzymes in HEK293H cells was carried out
using Lipofectamine 2000 transfection reagent (Invitrogen,
Karlsruhe, Germany), according to the manufacturer’s protocol.
Typically, prior to transfection, a mixture of plasmid DNA (0.8 mg)
and Lipofectamine 2000 transfection reagent (2 ml) in 100 ml of
serum-free DMEM or Opti-MEM medium (Invitrogen, Karls-
ruhe, Germany) was incubated at room temperature for 20 min
and applied to the cells thereafter. The cell layer was subsequently
incubated for 6 hours at 37uC, the medium containing the
transfection reagent was removed and 500 ml fresh DMEM was
added. In this step, the DGJ was added where intended. The cells
were incubated for another 60 hours and harvested.
Enzymatic measurement of a-galactosidase A
Cell pellets obtained from confluently grown 24-well cell culture
plates were homogenised in 200 ml water and subjected to 5
freeze-thaw cycles using liquid nitrogen. The supernatant collected
after centrifugation of the homogenate at 100006g for 5 min was
used in enzyme assays. Protein concentration was measured with
the BCA protein assay kit (Thermo Scientific, Braunschweig,
Germany) according to the manufacturer’s manual. 10 ml of the
cell lysates at a concentration of 50 mg/ml were assayed with 20 ml
of 4- MU-a-D-galactopyranoside (2 mM, Sigma Aldrich, Munich,
Germany) in 0.06 M phosphate citrate buffer (pH 4.7) with some
adaptations from the original method described by Desnick et al.
[40]. Enzyme reactions were terminated by the addition of 0.2 ml
of 1.0 M glycine buffer (pH 10.5), prepared by adjusting the pH
using 1.0 M NaOH. The released 4-MU was determined by
fluorescence measurement at 360 and 465 nm as the excitation
and emission wavelengths respectively, using a microplate
fluorescence reader (Tecan, Ma¨nnedorf, Switzerland). The mea-
sured enzyme activity was calculated as nmol 4-MU/mg protein
and normalised to one hundred percent wild-type activity.
Western blot analysis
Western blot analysis for the detection of a-Gal A protein was
performed using a custom made rabbit anti-a-Gal A polyclonal
antibody from Eurogentec, Cologne, Germany (animals were
immunised against peptides QRDSEGRLQADPQRFP (corre-
sponding to amino acids 99–114) and KQGYQLRQGDN-
FEVWE (corresponding to amino acids 326–341). Furthermore,
a mouse GAPDH monoclonal antibody 6C5 (Abcam, Cambridge,
UK) was used to visualise GAPDH as an internal loading control.
HEK293H cell lysates were generated by aspirating the media
from the 24-well culture plates, washing the cells once with 16
PBS (Biochrom AG, Berlin, Germany) and directly applying
200 ml ice cold RIPA buffer supplemented with protease inhibitor
cocktail tablets (Roche Applied Science, Penzberg, Germany)
prior to a 20 minute incubation on ice. The cells were then rinsed
from the wells, transferred to microcentrifuge tubes and spun at
140006g for 10 minutes at 4uC to pellet debris. The supernatant
was used for the analysis. 50 mg protein were mixed with a suitable
volume of 56Laemmli loading buffer, boiled for 5 minutes on a
thermo shaker, centrifuged at 140006g for 10 minutes at 4uC and
loaded on a Criterion precast 4–15% Tris-HCl gel (Bio-Rad,
Munich, Germany). Proteins were transferred electrophoretically
to a nitrocellulose (Amersham Hybond ECL) membrane (GE
Healthcare, Munich, Germany). The membrane was blocked with
5% (w/v) non-fat dried skimmed milk in TBS-Tween 20 [10 mM
Tris/HCl (pH 7.5) with 150 mM NaCl and 0.1% Tween 20] at
room temperature for 1 hour, and then treated with a primary
antibody against GAPDH diluted 1:10,000 in a milk/blot solution
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[3% (w/v) non-fat dried skimmed milk in TBS-Tween 20] at 4uC
overnight. The blot was then washed three times with excess TBS-
Tween 20 and treated with a primary antibody against a-Gal A
diluted 1:500 in the 3% milk/blot solution for 1 hour at room
temperature. After another wash procedure, a secondary antibody
mix of an Alexa Fluor labelled 680 goat anti-rabbit IgG antibody
(Molecular Probes, Karlsruhe, Germany) and an IRDye800
conjugated goat anti-mouse IgG antibody (Rockland-Biomol,
Hamburg, Germany) both diluted 1:10,000 in the 3% milk/blot
solution was applied to the membrane. Following extensive
washing with TBS-Tween 20, protein bands were visualised by
an Odyssey Infrared Imager (Li-Cor Biosciences, Linocln, NE,
USA). Quantification and protein size determination were
performed using the Odyssey software.
Determination of kinetic properties of a-galactosidase A
mutants
a-Gal A mutants were overexpressed in HEK293H cells.
60 hours after transfection in 24-well plates, the cells were
harvested in 100 ml H2O and the contents of two wells were
pooled. Cells were lysed by 5 freeze-thaw cycles and subsequent
centrifugation to obtain a cell-debris free lysate. Quantitative
Western blot analysis was carried out to reveal the ratio of the
mutant enzyme : wild type. The amount of lysate required to
obtain equal amounts of enzyme was calculated. Respective
quantities of wild type and mutant enzyme were subjected to the
kinetic evaluation described earlier [41]. Substrate concentrations
of 0.5, 1, 2, 4, 8 and 28 mM were assayed with constant amount of
enzyme in a Lineweaver Burk plot in order to obtain kinetic
parameters. To prove that equal amounts of input enzyme
(mutants and wild type) were employed for the assay, a-Gal A
content of the lysates was controlled with another Western blot
before applying the substrate. (Figure S2A). For standard curve, 5,
10, 20, 50 and 100 ng of agalsidase alpha (Replagal, Shire Human
Genetic Therapeutics, Dublin, Ireland) were subjected to Western
blot analysis and fluorescence values were plotted (see Figure S2B).
In the individual experiments between 2 and 6 ng of enzyme were
employed.
Lyso-Gb3 determination
As reference standards (Matreya LLC, USA; purity .98%) we
used lyso-ceramide trihexoside ( = lyso-globotriaosylsphingosi-
ne = lyso-Gb3). Internal standards were D5-fluticasone propionate
(EJY Tech., Inc. Rockville, MD, USA).
We used a gradient HPLC method on a reversed phase column
(ACE 3 C8, 5062.1 mm). The two HPLC pumps and the column
oven PE Series 200 were provided by Perkin Elmer, USA. The
mass spectrometer used was an API 4000 Q-Trap supplied by
Applied Biosystems, USA. The following experimental conditions
were used: column temperature 60uC, flow at 0.9 mL/min,
injection volume 10 mL, mobile phase with 50 mM formic acid in
water (A) and 50 mM formic acid in acetonitrile/acetone (1/
1= v/v; B), gradient at 5% B from 0 to 0.3 minutes, followed by a
linear gradient up to 73% B (0.3 to 2.6 minutes) and further on to
100% B (2.6 to 5.7 minutes). From 5.7 to 6.7 minutes 100% B was
used. Re-equilibration was done from 6.7 to 7.5 minutes at 5% B.
ESI in positive mode was used for peak detection.
The detection mode was MRM, the vaporizer temperature was
set at 500uC, ionisation voltage was 5.5 kV, curtain gas pressure
was 40 psi. Lyso-Gb3 quantifier was 786.6 to 282.2 m/z and
506.3 to 313.0 m/z for the internal standard D5-fluticasone
propionate.
For the sample analysis, 50 ml aliquots were used. 100 ml of
internal standard working solution (in ethanol) were added.
Samples were mixed for about 30 seconds and centrifuged at
4,000 rpm for 2 minutes. The clear supernatant was transferred
into appropriate auto sampler vials which were closed thereafter
with crimp caps. Normal and pathological values were determined
in 145 healthy controls and 275 Fabry patients with genetically
confirmed disease.
Selection of mutations
The following criteria influenced the decisions whether a given
mutant was to be included in the study:
1. The mutation was novel or has not been well described (no
biochemical activity data were available; N= 138)
2. The mutation lead to a single amino acid substitution (N= 147)
3. Patient-derived data (phenotype severity, biomarker lyso-Gb3)
are available (N= 100)
4. Three sites (R118, S126, D264) were selected for ‘‘permuting’’
the native amino acid into every possible residue resulting from
single nucleotide exchanges. R118C and S126G are involved
in variant forms of the FD phenotype and found to be more
prevalent (9, own data). D264V/Y are involved in classical FD
(N=15)
Statistical analysis
We used Sperman’s rho (rs) rank correlation coefficient to test
associations between GLA level and enzyme activity (Figure 1).
Linear trend tests were used to test associations between two ordinal
variables, for example enzyme activity class and DGJ responsiveness
(Table 1). To compare the predictive values of female lyso-Gb3
values, male lyso-Gb3 values, in vitro enzyme activity and PolyPhen2-
scores with regard to clinical phenotype on the mutation level we used
ordinal regression with only one of the four different prediction
measures as the independent variable and with ‘clinical phenotype’ as
the outcome. This regression analysis was performed for all mutations
where values on specific prediction measure and the outcome were
available. For comparison we repeated the regression analysis for the
21 mutations of which values for all four measures were available
(Table 2). We used Nagelkerke’s R-Square as a measure of explained
variance, the 22 Log-Likelihood as a measure of Goodness of Fit of
the model and the proportion of correct classified mutations. All
analyses were done using IBM SPSS Statistics, Release 20.0.0 (SPSS,
Inc., 2011, Chicago, IL, www.spss.com).
Supporting Information
Figure S1 Detailed view of the employed analysis. Applied to
analysis were residual enzyme activity with (black bars) or without
(grey bars) the addition of 20 mM DGJ to the medium and the
respective change in cellular protein level semi-quantitatively
calculated on a fluorescence reader. The Western Blot method
used here was not able to detect endogenously expressed a-Gal A
enzyme. Values are mean 6 SEM. *p,0.05, **p,0.01,
***p,0.005.
(TIF)
Figure S2 A. Control Western Blot. Semiquantitative analysis of
a-Gal A level determined by Western Blot were used to examine
kinetic properties of the mutant enzymes compared to the wild
type. B. Recombinant enzyme agalsidase alpha used for Enzyme
Replacement Therapy was kindly provided by Shire Human
Genetics Therapies to estimate total amount subjected to the
kinetic assay [see Material and Methods section]
(TIF)
Functional Characterisation of GLA Mutations
PLOS Genetics | www.plosgenetics.org 8 August 2013 | Volume 9 | Issue 8 | e1003632
Table S1 Overview of mutations tested in vitro for enzyme
activity. Number of experiments (enzyme activity) and patient
numbers (lyso-Gb3) are indicated in brackets. The a-Gal A activity
limit of quantification (LOQ) in HEK293H cells was defined as
235.3 nmol 4-MU/mg protein for untreated mutations and
292.5 nmol 4-MU/mg protein for 20 mM DGJ treated mutations,
respectively, which accounts for 95% of the values obtained from
empty vector only transfections. Number of experiments (enzyme
activity) and patient numbers (lyso-Gb3) are indicated in brackets.
Note that even though females have much lower values of lyso-
Gb3 all 6 mutations that caused no elevated lyso-Gb3 in males
likewise caused no elevation in females (where applicable),
indicating that these mutations may not lead to an accumulation.
wDisease phenotype is conventionally divided into classic, variant
and classic/variant. The latter is used for mutations where variant
and classic types of FD are reported or a mild classical phenotype
is observed. YMutations have not been described in patients yet.
**F396Y was terminated from HGMD. Not a genomic mutation is
responsible for the finding. As underlying mechanism RNA editing
was proposed.
(DOC)
Table S2 Association of in vitro enzyme activity with biochemical
and crystallographic data. In vitro enzyme activity is associated with
the responsiveness to pharmacological chaperone DGJ. As another
biochemical parameter DGJ responsiveness is demonstrated to be
associated to residual enzyme activity. Enzyme activity shows only
a weak linear trend with the parameter ‘‘accessible surface area’’
obtained from crystallographic studies. Accessible surface area is
defined as the ‘‘average accessibility of each atom in the residue’’
[33]. However, this model does not take active site residues with a
usually high surface accessibility that display low residual activity
into consideration. Cut points for accessible surface area were
extracted from Garman (2007) [33].
(DOC)
Table S3 Lyso-Gb3 values of classic or presumed classic
mutations. Lyso-Gb3 was measured in male and female Fabry
patients. The mean is displayed in the table. Generally males have
much higher lyso-Gb3-levels than females. With three exceptions
(data obtained from one female patient harbouring the mutation
p.A20P, p.W262*, p.W399*, respectively) all of the mutations
shown here caused elevated lyso-Gb3 values above the patholog-
ical cut-off of 0.9 ng/ml. * All females are heterozygotes.
(DOC)
Table S4 Kinetic properties of a-Gal A mutants. Asterisks
indicate a significant change towards the wild type enzyme
(p,0.05). Agalsidase alfa has been tested to validate comparability
of the assay.
(DOC)
Table S5 Putative impact on splicing. A: Effect of missense
mutations on natural acceptor and donor splicing sites. Analysis of
the splice-sites revealed 3 possible splice-site abolishments. B:
Effect of missense mutations on cryptic and novel acceptor and
donor sites. The analysis suggested possible changes in 3 sites
involving the activation of cryptic and novel donor/acceptor sites.
Note: the range of values is given in parenthesis for each splicing
algorithm.
(DOC)
Text S1 Additional method. Description of the method applied
to reveal alterations of mRNA splicing.
(DOC)
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